retatrutide phase 2 trial obesity nejm 2023 triple agonist Hormone Receptor Agonist: Mechanism, Evidence, and UK Status – Bolt Pharmacy Lilly Reports Up to 28.3%

Participants maintaining the highest 12 mg dose of retatrutide lost an average of 30.3% of their body weight (38.5 kg) at 104 weeks, while those moving from the lowest 4 mg dose to the maximum tolerated dose lost an average of 27.9% of their body weight (33.2 kg)

Zolmitriptan (Oral route)

Individuals with complex medical histories, multiple medications, or conditions requiring physical examination may benefit from an in-person provider relationship

Weight Loss and Obesity Treatment In addition to their role in managing type 2 diabetes, GLP-1 agonists have gained significant attention for their potential in promoting weight loss and treating obesity